<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03291288</url>
  </required_header>
  <id_info>
    <org_study_id>PL3397-A-U126</org_study_id>
    <nct_id>NCT03291288</nct_id>
  </id_info>
  <brief_title>Effect of Pexidartinib on the Way the Body Processes CYP3A4 and CYP2C9 Substrates (Pharmacokinetics)</brief_title>
  <official_title>An Open-label, Single Sequence, Crossover Drug-drug Interaction Study Assessing the Effect of Pexidartinib on the Pharmacokinetics of CYP3A4 and CYP2C9 Substrates in Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daiichi Sankyo, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daiichi Sankyo, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study has two parts.

      Part 1 will evaluate how pexidartinib affects the way the body processes CYP3A4 and CYP2C9
      substrates using midazolam and tolbutamide, respectively, as probe agents.

      Part 2 will test the efficacy and safety of pexidartinib treatment in various tumor types.

      In Part 2, the same participants will continue to receive pexidartinib twice daily.

      Participants will be allowed to continue using pexidartinib as long as the participant
      derives benefit.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 26, 2018</start_date>
  <completion_date type="Anticipated">March 2019</completion_date>
  <primary_completion_date type="Anticipated">March 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Open-label, single sequence study with 2 parts</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum concentration (Cmax) for midazolam</measure>
    <time_frame>within 15 days</time_frame>
    <description>Plasma samples for midazolam will be collected at predose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 24, and 48 h (±10 min up to 1 h, ±10% thereafter) on Days 1 to 3, and also when co-administered with pexidartinib on Days 3 (to 5) and Days 13 (to 15)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax for tolbutamide</measure>
    <time_frame>within 15 days</time_frame>
    <description>Plasma samples for tolbutamide will be collected at predose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 24, and 48 h (±10 min up to 1 h, ±10% thereafter) on Days 1 to 3, and also when co-administered with pexidartinib on Days 3 (to 5) and Days 13 (to 15)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to maximum concentration (Tmax) for midazolam</measure>
    <time_frame>within 15 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax for tolbutamide</measure>
    <time_frame>within 15 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the curve to the last observable concentration (AUClast) for midazolam</measure>
    <time_frame>within 15 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUClast for tolbutamide</measure>
    <time_frame>within 15 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with an adverse event by the end of Part 2</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall response rate (ORR) by the end of Part 2</measure>
    <time_frame>1 year</time_frame>
    <description>ORR is defined as the percentage of participants who achieve a confirmed complete response (CR) or partial response (PR) based on locally read tumor assessments according to Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1 or other applicable assessment of treatment response based upon the applicable tumor.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax for pexidartinib and its metabolites</measure>
    <time_frame>within 13 days</time_frame>
    <description>Plasma samples for pexidartinib and its metabolite will be collected at predose, 0.5, 1, 2, 2.5, 3, 4, 6, 8, and 10 (±1) h after the first dose on Day 3, and at steady state when co-administered with midazolam and tolbutamide on Day 13.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax for pexidartinib and its metabolite</measure>
    <time_frame>within 13 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUClast for pexidartinib and its metabolite</measure>
    <time_frame>within 13 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax for midazolam metabolite</measure>
    <time_frame>within 13 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax for midazolam metabolite</measure>
    <time_frame>within 13 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUClast for midazolam metabolite</measure>
    <time_frame>within 13 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metabolite to parent ratio (MPR) for midazolam</measure>
    <time_frame>within 13 days</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Drug Interaction Potential</condition>
  <arm_group>
    <arm_group_label>Part 1 - Reference treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>On Day 1 all participants will receive a single oral dose each of midazolam (2 mg) and tolbutamide (500 mg), followed by blood draws for pharmacokinetic (PK) analysis.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1 - Test Treatment 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>On Day 3 all participants will receive a single oral dose each of midazolam (2 mg) and tolbutamide (500 mg) with morning dose of pexidartinib (400 mg) followed by blood draws for PK analysis.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1 - Test Treatment 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All participants will receive only the 400 mg pm dose of pexidartinib on Day 3 and continue twice-daily (BID) dosing of pexidartinib (400 mg for the am dose, and 400 mg for the pm dose) until Day 13.
On Day 13, all participants will receive a single oral dose of midazolam (2 mg) and tolbutamide (500 mg) with the morning dose of pexidartinib (400 mg) followed by blood draws for PK analysis.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 - Pexidartinib only</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>On Day 13, all participants will receive a pm dose of 400 mg pexidartinib only.
All participants will continue to receive pexidartinib BID dosing in 28-day cycles at the 400 mg/day dose for up to one year. The dose of pexidartinib may be further modified within that year, depending upon tolerance as defined in the protocol.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tolbutamide</intervention_name>
    <description>Commercially available tolbutamide</description>
    <arm_group_label>Part 1 - Reference treatment</arm_group_label>
    <arm_group_label>Part 1 - Test Treatment 1</arm_group_label>
    <arm_group_label>Part 1 - Test Treatment 2</arm_group_label>
    <other_name>Orinase</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Midazolam</intervention_name>
    <description>Commercially available midazolam</description>
    <arm_group_label>Part 1 - Reference treatment</arm_group_label>
    <arm_group_label>Part 1 - Test Treatment 1</arm_group_label>
    <arm_group_label>Part 1 - Test Treatment 2</arm_group_label>
    <other_name>Dormicum</other_name>
    <other_name>Hypnovel</other_name>
    <other_name>Versed</other_name>
    <other_name>Others</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pexidartinib</intervention_name>
    <description>Pexidartinib is formulated as opaque, white, 200-mg capsules</description>
    <arm_group_label>Part 1 - Test Treatment 1</arm_group_label>
    <arm_group_label>Part 1 - Test Treatment 2</arm_group_label>
    <arm_group_label>Part 2 - Pexidartinib only</arm_group_label>
    <other_name>PLX-3397</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Is the age of majority in country of residence

          -  Has a diagnosis of:

               1. tenosynovial giant cell tumor (TGCT), which is associated with severe morbidity
                  or functional limitations and for whom surgery is not an option (prior
                  pexidartinib is permitted for TGCT patients unless ineffective or not tolerated
                  and there has been a washout period of at least 4 weeks)

               2. KIT-mutant tumor, including melanoma or gastrointestinal stromal tumor (GIST),
                  for which there is no standard systemic therapy, or

               3. other solid tumors (all comers) for which there is no standard systemic therapy
                  and there is a rationale for use of pexidartinib at the Investigator's discretion

          -  If a female of childbearing potential, had a negative serum pregnancy test within 14
             days before enrollment, or within 72 hours before enrollment where required

          -  Is a non-sterile male or female willing to use of one of the protocol-defined highly
             effective contraception methods:

               1. intra-uterine device (nonhormonal or hormonal)

               2. sexual abstinence (only if this is in line with the patient's current lifestyle)

               3. barrier methods (eg, condom, diaphragm) used in combination with hormonal methods
                  associated with inhibition of ovulation

          -  Is a surgically sterile male or female, or is postmenopausal for at least 1 year, at
             least 50 years of age, with a follicle-stimulating hormone level &gt; 40
             milli-International units per mL (mIU/mL)

          -  Has adequate hematologic, hepatic, and renal function as defined by the protocol

          -  Is able and willing to follow all study procedures

          -  Has provided a signed informed consent

        Exclusion Criteria:

          -  Is pregnant or breastfeeding

          -  Is unable to swallow oral medication

          -  Is unable to follow study procedures

          -  Is taking or has taken any medications or therapies outside of protocol-defined
             parameters

          -  Has any disease or condition that, per protocol or in the opinion of the investigator,
             might affect:

               1. safety and well-being of the participant or offspring

               2. safety of study staff

               3. analysis of results
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Clinical Leader</last_name>
    <role>Study Chair</role>
    <affiliation>Daiichi Sankyo, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>HonorHealth</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Coordinator</last_name>
      <phone>480-323-1348</phone>
      <email>Jeffrey.dolim@honorhealth.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Arizona</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85719</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Coordinator</last_name>
      <phone>520-694-9082</phone>
      <email>kris7c@email.arizona.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Coordinator</last_name>
      <phone>650-723-2868</phone>
      <email>shmonshi@stanford.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Kansas Cancer Center</name>
      <address>
        <city>Westwood</city>
        <state>Kansas</state>
        <zip>66205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Coordinator</last_name>
      <phone>913-945-7551</phone>
      <email>xlam@kumc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Coordinator</last_name>
      <phone>617-582-7503</phone>
      <email>ssolomon1@partners.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Center</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Coordinator</last_name>
      <phone>313-576-9749</phone>
      <email>schneidk@karmanos.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>718-405-8515</phone>
      <email>mhghalib@montefiore.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Northwell Health</name>
      <address>
        <city>Lake Success</city>
        <state>New York</state>
        <zip>10042</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Coordinator</last_name>
      <phone>516-734-7629</phone>
      <email>esham@northwell.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mary Crowley Cancer Research</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Coordinator</last_name>
      <phone>214-658-1985</phone>
      <email>nkarimi@marycrowley.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Washington/ Seattle Cancer Care Alliance</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>The Research Institute for Future Medicine</name>
      <address>
        <city>Seoul</city>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Leids Universitair Medisch Centrum</name>
      <address>
        <city>Leiden</city>
        <zip>2333 ZA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Coordinator</last_name>
      <phone>+31 715261965</phone>
      <email>j.ouwerkerk@lumc.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Christchurch Hospital NZ</name>
      <address>
        <city>Christchurch</city>
        <zip>8011</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Coordinator</last_name>
      <phone>+64 33786282</phone>
      <email>Rachel.hart@cdhb.health.nz</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>10002</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Coordinator</last_name>
      <phone>886-223123456</phone>
      <phone_ext>67460</phone_ext>
      <email>lovelyeffie@ntuh.gov.tw</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
    <country>Netherlands</country>
    <country>New Zealand</country>
    <country>Taiwan</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 19, 2017</study_first_submitted>
  <study_first_submitted_qc>September 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 25, 2017</study_first_posted>
  <last_update_submitted>May 8, 2018</last_update_submitted>
  <last_update_submitted_qc>May 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tenosynovial Giant Cell Tumors (TGCT)</keyword>
  <keyword>Kit-mutant melanoma</keyword>
  <keyword>Kit-mutant gastrointestinal stromal tumor (GIST)</keyword>
  <keyword>Cocktail drug-drug interaction (DDI)</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Midazolam</mesh_term>
    <mesh_term>Tolbutamide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>De-identified individual participant data (IPD) and applicable supporting clinical trial documents may be available upon request at http://www.clinicalstudydatarequest.com. In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants. Details on data sharing criteria and the procedure for requesting access can be found at this web address: https://www.clinicalstudydatarequest.com/Study-Sponsors-DS-Details.aspx</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

